Lafarze Tablet is a combination pharmaceutical formulation containing Diacerein 50 mg and Glucosamine 750 mg, indicated primarily for the management of osteoarthritis and related degenerative joint disorders. Diacerein, an anthraquinone derivative, exhibits anti-inflammatory and chondroprotective properties by inhibiting interleukin-1 beta, thereby reducing cartilage degradation and alleviating joint pain and stiffness. Glucosamine, a naturally occurring amino monosaccharide, serves as a precursor in the biosynthesis of glycosaminoglycans and proteoglycans, essential components of cartilage matrix, promoting cartilage repair and improving joint function. The synergistic effect of these agents in Lafarze Tablet aims to slow disease progression, enhance joint mobility, and improve patient quality of life. It is recommended for oral administration, with dosage and duration tailored according to clinical response and physician guidance. Common adverse effects may include mild gastrointestinal disturbances such as diarrhea, abdominal pain, or nausea. Lafarze Tablet should be used cautiously in patients with hepatic or renal impairment, and is contraindicated in individuals with hypersensitivity to any component of the formulation. Regular monitoring and adherence to prescribed dosage are essential to optimize therapeutic outcomes and minimize potential risks.